NCT06778434View on ClinicalTrials.gov

The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms on US Veterans

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

March 30, 2029

Study Completion Date

March 30, 2029

Conditions
Actinic KeratosisImipraminePhotodynamic Therapy
Interventions
DRUG

Imipramine

10% imipramine

OTHER

Control Vehicle

polyethylene glycol: dimethyl sulfoxide Solution

Trial Locations (1)

45428

RECRUITING

Dayton VA Medical Center, Dayton, OH, Dayton

All Listed Sponsors
lead

VA Office of Research and Development

FED